Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease
JAMA · 2026
DOI: 10.1001/jama.2026.9379 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA, 2026. Verfasst von Sunil V Badve und 37 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Factor Xa Inhibitors, Hemorrhage, Kidney Failure, Chronic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Approximately 10% to 15% of patients with advanced chronic kidney disease (CKD) experience a fatal or nonfatal cardiovascular event annually. The effects of antithrombotic therapies on cardiovascular events in patients with advanced CKD are unknown.
Objective
To determine whether low-dose rivaroxaban reduces rates of adverse cardiovascular events compared with placebo in patients with advanced CKD. Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial conducted at 90 centers in 12 countries. Eligible participants were adults with CKD stage 4 or 5 and patients with dialysis-dependent kidney failure. Participants had a history of either coronary artery disease; nonhemorrhagic, nonlacunar stroke; peripheral artery disease; diabetes; or were 65 years or older. Enrollment occurred between January 2021 and July 2025. The trial was stopped early on August 7, 2025, for lack of efficacy. Final follow-up occurred on October 30, 2025. Statistical analyses were conducted in February and March 2026.
Interventions
Patients were randomized 1:1 to receive rivaroxaban 2.5 mg twice daily or placebo. Main Outcomes and Measures The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, stroke, or a peripheral artery disease event. The primary safety outcome was major bleeding.
Results
Of 1458 randomized patients (mean [SD] age, 63.2 [11.6] years, 432 [29.6%] female), 1360 (93.3%) completed follow-up. During a median follow-up of 1.7 years, the primary outcome occurred in 164 patients (22.6%) in the low-dose rivaroxaban group and 151 (20.7%) in the placebo group (13.0 vs 11.8 events per 100 person-years; hazard ratio, 1.09 [95% CI, 0.87-1.36]; P = .46). Major bleeding occurred in 64 patients (8.8%) receiving low-dose rivaroxaban and 44 (6.0%) receiving placebo (5.1 vs 3.4 events per 100 person-years; hazard ratio, 1.51 [95% CI, 1.02-2.22]; P = .04). Conclusions and Relevance In patients with advanced CKD at high cardiovascular risk, low-dose rivaroxaban did not reduce the risk of a composite cardiovascular outcome. Major bleeding rates were significantly higher in the low-dose rivaroxaban group compared with the placebo group. Trial Registration ClinicalTrials.gov Identifier: NCT03969953
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
- Department of Renal Medicine, St George Hospital, Sydney, New South Wales, Australia.
- University of New South Wales, Sydney, New South Wales, Australia.
- School of Public Health, Imperial College London, London, United Kingdom.
- Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India.
- Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Zitieren
APA
Badve, S. V., Perkovic, V., Jha, V., Ramachandran, R., Mushahar, L., Menne, J., De Vriese, A. S., Rossignol, P., Flahault, A., Al Ammari, M., Skhiri, H., Walsh, M., Collister, D., Liew, A., Billot, L., Bompoint, S., Devaux, A., Jun, M., Lin, E., …, & TRACK Trial Investigators (2026). Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease. JAMA. https://doi.org/10.1001/jama.2026.9379
Vancouver
Badve SV, Perkovic V, Jha V, Ramachandran R, Mushahar L, Menne J, et al. Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease. JAMA. 2026. doi:10.1001/jama.2026.9379
BibTeX
@article{Badve2026,
author = {Badve, Sunil V and Perkovic, Vlado and Jha, Vivekanand and Ramachandran, Raja and Mushahar, Lily and Menne, Jan and De Vriese, An S and Rossignol, Patrick and Flahault, Adrien and Al Ammari, Maha and Skhiri, Habib and Walsh, Michael and Collister, David and Liew, Adrian and Billot, Laurent and Bompoint, Severine and Devaux, Anthony and Jun, Min and Lin, Enmoore and Ramos da Cruz, Aline and Ha, Jeffrey T and Eikelboom, John W and Shaman, Ahmed and Jardine, Meg J and Jesudason, Shilpanjali and Wong, Muh Geot and Anderson, Craig S and Garg, Amit X and Heerspink, Hiddo J L and Monaghan, Helen and Patel, Anushka and Mark, Patrick B and Wheeler, David C and Lv, Jicheng and Zuo, Li and Pilmore, Helen and Gallagher, Martin and TRACK Trial Investigators, TRACK Trial Investigators},
title = {Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2026.9379}
}
EUVIMED